[1] KURMI B D, TEKCHANDANI P, PALIWAL R, et al. Transdermal drug delivery: Opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers [J]. Current Drug Metabolism, 2017, 18: 481-95. [2] IBRAHIM Z A, HASSAN G F, ELGENDY H Y, et al. Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo [J]. Journal of Cosmetic Dermatology, 2018: DOI=10.1111/jocd.12704. [3] AMMAR H O, GHORAB M, EL-NAHHAS S A, et al. Design of a transdermal delivery system for aspirin as an antithrombotic drug [J]. International Journal of Pharmaceutics, 2006, 327: 81-88. [4] SIXEL-DORING F, TRENKWALDER C. Rotigotine transdermal delivery for the treatment of restless legs syndrome [J]. Expert Opinionon Pharmacotherapy, 2010,11: 649-656. [5] JIANG T, WANG T, LI T, et al. Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma [J]. ACS NANO, 2018, 12 (10): 9693-9701. [6] BROWN M B, MARTIN G P, JONES S A, et al. Dermal and transdermal drug delivery systems: Current and future prospects [J]. Drug Delivery, 2006, 13: 175-187. [7] COURTENAY A J, MCCRUDDEN M T C, MCAVOY K J, et al. Microneedle-mediated transdermal delivery of bevacizumab[J]. Molecular Pharmaceutics [J]. 2018,15: 3545-3556. [8] CEFALU W T. Concept, strategies, and feasibility of noninvasive insulin delivery [J]. Diabetes Care, 2004, 27: 239-246. [9] CHEN Y, SHEN Y, GUO X, et al. Transdermal protein delivery by a coadministered peptide identified via phage display [J]. Nature Biotechnology, 2006, 24: 455-460. [10] RUAN R Q, WANG S S, WANG C L, et al. Transdermal delivery of human epidermal growth factor facilitated by a peptide chaperon [J]. European Journal of Medicinal Chemistry, 2013, 62: 405-409. [11] JIN P P, LI F F, RUAN R Q, et al. Enhanced transdermal delivery of epidermal growth factor facilitated by dual peptide chaperone motifs [J]. Protein and Peptide Letters, 2014, 21: 550-555. [12] HERMAN A, HERMAN A P. Mechanism of action of herbs and their active constituents used in hair loss treatment [J]. Fitoterapia, 2016, 114: 18-25. [13] WU Z, SUN L, LIU G, et al. Hair follicle development and related gene and protein expression of skins in Rex rabbits during the first 8 weeks of life [J]. Asian-Australasian Journal of Animal Sciences, 2018: DOI= 10.5713/ajas.18.0256. [14] BICHSEL K J, GOGIA N, MALOUFF T, et al. Role for the epidermal growth factor receptor in chemotherapy-induced alopecia [J]. PLoS ONE, 2013, 8(7): e69368. [15] PAIK S H, YOON J S, RYU H H, et al. Pretreatment of epidermal growth factor promotes primary hair recovery via the dystrophic anagen pathway after chemotherapy-induced alopecia[J]. Experimental Dermatology, 2013, 22(7): 496-499. [16] WEE P, WANG Z. Epidermal growth factor receptor cell proliferation signaling pathways [J]. Cancers, 2017, 9(5): 52. [17] HUYNH E, LI J. Generation of Lactococcus lactis capable of coexpressing epidermal growth factor and trefoil factor to enhance in vitro wound healing [J]. Applied Microbiology and Biotechnology, 2015, 99(11): 4667-4677. [18] WALTER M N, WRIGHT K T, FULLER H R, et al. Mesenchymal stem cell-conditioned medium accelerates skin wound healing: An in vitro study of fibroblast and keratinocyte scratch assays [J]. Experimental Cell Research, 2010, 316(7): 1271-1281. [19] LUSK J B, LAM V Y, TOLWINSKI N S. Epidermal growth factor pathway signaling in drosophila embryogenesis: Tools for understanding cancer [J]. Cancers, 2017, 9(2): 16. [20] XING X J, YANG L, YOU Y, et al. Study of the biological function and penetration pathways of the mouse epidermal growth factor ethosomal delivery system [J]. Experimental Dermatology, 2011, 20(11): 945-947.
|